+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination



Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination



Bmc Ophthalmology 10: 10



Given the growing number of ocular hypotensive medications available, it is important to be able to predict a positive response to therapy. The purpose of the present study was to identify predictors of an additional 10% intraocular pressure (IOP) reduction after 12 weeks of treatment with latanoprost/timolol fixed combination (FC) in patients requiring a change in their previous ocular hypotensive medication. This multicenter, open-label, prospective, phase IIIb study included subjects >or=18 years of age with open-angle glaucoma (OAG) or ocular hypertension (OHT). Eligible subjects had baseline IOP >or=21 mmHg and insufficient response to current beta-blocker monotherapy. The primary efficacy analysis (logistic regression) identified predictors of a positive response after 12 weeks of latanoprost/timolol FC. The intent-to-treat (ITT) population included 383 subjects treated with >or=1 drop of FC and having >or=1 follow-up IOP assessment. Mean IOP was 22.19 +/- 2.16 mmHg at baseline and was reduced by 5.42 +/- 2.71 mmHg at study end. In all, 325 (84.9%) subjects had a positive response to latanoprost/timolol FC; the response rate was similar across groups: OAG (n = 208; 82.7%); OHT (n = 161; 87.6%); OAG+OHT (n = 14; 85.7%). Higher baseline IOP (odds ratio: 1.284; 95% confidence interval [CI]: 1.101, 1.497; p = 0.0014) and absence of adverse events (odds ratio: 0.318; 95% CI: 0.161, 0.629; p = 0.0010) were significant predictors of positive response. Age, gender, ethnic origin, diagnosis, family history of OAG/OHT, corneal thickness, and concomitant systemic beta-blocker were not significant predictors of a positive response in the ITT analysis. The FC was well tolerated. The most common adverse events were related to the eye and were consistent with known adverse events associated with latanoprost and timolol. These results support the use of latanoprost/timolol FC in patients whose IOP is insufficiently controlled on beta-blocker monotherapy. Patients with higher baseline IOP levels and who do not experience adverse events while on therapy are most likely to achieve a positive response to latanoprost/timolol FC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055109821

Download citation: RISBibTeXText

PMID: 20346127

DOI: 10.1186/1471-2415-10-10


Related references

A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Current Medical Research and Opinion 23(5): 1025-1032, 2007

The Effects of Fixed Combination of Bimatoprost-Timolol and Travoprost-Timolol on Intraocular Pressure in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension, Previously on Nonfixed Combination of Latanoprost and Timolol. Asia-Pacific Journal of Ophthalmology 1(4): 208-212, 2012

A Comparison of Fixed Combination of Latanoprost and Timolol with Fixed Combination of Dorzolamide and Timolol in Patients With Elevated Intraocular Pressure A Three-month Masked Evaluator, Phase IIIb, Multicenter Study in the United States. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 295, 2002

24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension. Journal of the Medical Association of Thailand 94(Suppl. 2): S81-S87, 2011

The Efficacy of a Latanoprost/Timolol Fixed Combination Versus Latanoprost and Timolol Gel-forming Solution Unfixed Combination on Daytime Intraocular Pressure. Journal of Glaucoma 25(2): 135-139, 2016

Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. Journal of Glaucoma 19(5): 331-335, 2010

Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy. British Journal of Ophthalmology 94(1): 80-84, 2010

A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe. British Journal of Ophthalmology 88(7): 877-883, 2004

Efficacy and safety of the fixed combination latanoprost/timolol versus the unfixed combination brimonidine/timolol in patients with elevated intraocular pressure a 6 month, masked evaluator study. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 2198, 2003

Twenty-four-hour intraocular pressure control with latanoprost-timolol-fixed combination versus bimatoprost in patients who switched from timolol. Journal of Glaucoma 20(8): 477-481, 2011

Diurnal intraocular pressure with bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in healthy subjects. Korean Journal of Ophthalmology 28(1): 39-48, 2014

Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol dorzolamide-combination. Eye 19(2): 145-151, 2005

Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database. Current Medical Research and Opinion 24(10): 2725-2728, 2008

24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Current Eye Research 34(5): 369-377, 2009

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg. Clinical Ophthalmology 3: 337-339, 2009